• 06.06.19

    Extending VBP Models Into Medicaid Drug Purchasing

    States are using several different models to extend VBP strategies into their drug purchasing.

  • 03.25.19

    New Medicaid Briefing Series: Priority Issues for State Lawmakers

    Where  the agency and its leadership sit within state government can enable or impede the Medicaid director’s authority to make critical decisions about strategy, services and budget.

  • 08.30.18

    CMS Releases Guidance Formalizing Budget Neutrality Policies

    On August 22, 2018, the Centers for Medicare & Medicaid Services (CMS) released a State Medicaid Director Letter (SMDL) memorializing its long-standing budget neutrality policies requiring that waivers under Section 1115 of the Social Security Act (1115 waivers) cost no more to the federal ...

  • 07.30.18

    CMS Responds to States’ Drug Pricing Proposals

    The Trump administration (the Administration) has called for a reduction in drug spending.

  • 06.26.18

    Virginia Expands Medicaid

    On June 7, 2018, Virginia joined 32 other states and the District of Columbia in expanding Medicaid under the Affordable Care Act to adults with incomes at or below 138% of the federal poverty level (FPL).

  • 05.24.18

    Is Momentum for Medicaid Expansion on the Upswing?

    To date, 33 states, including the District of Columbia, have expanded Medicaid under the Affordable Care Act (ACA) to adults with incomes at or below 138% of the federal poverty level (FPL)—newly covering more than 12 million Americans by the end of 2015.

  • 03.28.18

    Medicaid’s Critical Role in Addressing the Opioid Crisis

    As the opioid crisis in the United States continues to deepen—with opioid overdoses claiming 42,000 lives in 20161—policymakers, providers, advocates and other stakeholders are seeking out all available resources in an attempt to fight back.

  • 02.27.18

    Efforts to Cut Drug Prices in Medicaid

    Over the past five years, the budgets of state Medicaid programs have been challenged by the introduction of new high-cost drugs into the marketplace.

  • 01.25.18

    The Eight Key Elements of Effective Compliance Programs

    Mandated compliance programs are not a new concept, but they have evolved over time.

  • 12.18.17

    Part 1: Megatrends Reinventing How Patients Think

    In early 2017, California Assembly member Jim Wood introduced Bill AB-265, banning the use of copay coupons in California when a generic equivalent drug covered by an individual’s health plan exists.